Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 2019-08, Vol.121 (5), p.429-430
Hauptverfasser: Gorbunova, Vera, Beck, J. Thaddeus, Hofheinz, Ralf-Dieter, Garcia-Alfonso, Pilar, Nechaeva, Marina, Gracian, Antonio Cubillo, Mangel, Laszlo, Fernandez, Elena Elez, Deming, Dustin A., Ramanathan, Ramesh K., Torres, Alison H., Sullivan, Danielle, Luo, Yan, Berlin, Jordan D.
Format: Artikel
Sprache:eng
Schlagworte:
631/67/1504/1885
692/308/2779/109/1941
692/699/1503/1504/1885
692/699/67/1059/99
Biomedical and Life Sciences
Biomedicine
Cancer Research
Colorectal carcinoma
Correction
Drug Resistance
Epidemiology
Molecular Medicine
Oncology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be accessed via a link at the top of the paper.
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-019-0528-0